TCGA-86-8075-01A-11R-2241-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- TGF_BETA_SIGNALING+0.500
- TNFA_SIGNALING_VIA_NFKB+0.490
- INTERFERON_ALPHA_RESPONSE+0.470
- PROTEIN_SECRETION+0.450
- UV_RESPONSE_DN+0.450
- NOTCH_SIGNALING+0.440
- INTERFERON_GAMMA_RESPONSE+0.420
- KRAS_SIGNALING_UP+0.390
- ANGIOGENESIS+0.380
Top 10 suppressed
- MYC_TARGETS_V2-0.410
- PANCREAS_BETA_CELLS-0.410
- OXIDATIVE_PHOSPHORYLATION-0.340
- MYC_TARGETS_V1-0.270
- SPERMATOGENESIS-0.220
- KRAS_SIGNALING_DN-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- FATTY_ACID_METABOLISM-0.160
- XENOBIOTIC_METABOLISM-0.100
- E2F_TARGETS-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-8055-01A-11R-2241-07 | — | cohortA1 | 0.927 |
| 2 | TCGA-86-8074-01A-11R-2241-07 | — | cohortA1 | 0.880 |
| 3 | MDT-AP-3280 | Med | Medulloblastoma | 0.876 |
| 4 | SJEPD032296_D1.RNA-Seq | EPN | Anaplastic EPN | 0.869 |
| 5 | SRR934726 | — | — | 0.868 |
| 6 | TCGA-97-7554-01A-11R-2039-07 | — | cohortA1 | 0.858 |
| 7 | TCGA-64-1679-01A-21R-2066-07 | — | cohortA1 | 0.855 |
| 8 | efe57fc7-7cf4-432b-86ff-9fd2d1a37b5e | — | — | 0.854 |
| 9 | TCGA-FD-A3SP-01A-31R-A22U-07 | — | — | 0.846 |
| 10 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.370 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |